Bicalutamide is a competitive antagonist that does allow AR to bind DNA[22]; however, in the setting of castrate-resistant prostate cancer, bicalutamide can exhibit an antagonist-to-agonist shift as demonstrated clinically by a decline in prostate-specific antigen following bicalutamide (Casodex) withdrawal[23]. This evidence concerns the gene AR and prostate carcinoma.